Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jean Lang

Showing results (21-30 of 53) with videos related to

Pageof 6
Sort By:
Vaccine|October 11, 2005
Immunogenicity and safety of two live-attenuated tetravalent dengue vaccine formulations in healthy Australian adultsScott Kitchener, Michael Nissen, Peter Nasveld, et al.
Journal of Virology|March 30, 2018
Improvement of the Dengue Virus (DENV) Nonhuman Primate Model via a Reverse Translational Approach Based on Dengue Vaccine Clinical Efficacy Data against DENV-2 and -4Veronique Barban, Nathalie Mantel, Aymeric De Montfort, et al.
The Journal of Infectious Diseases|December 15, 2010
Different innate signatures induced in human monocyte-derived dendritic cells by wild-type dengue 3 virus, attenuated but reactogenic dengue 3 vaccine virus, or attenuated nonreactogenic dengue 1-4 vaccine virus strainsClaire Balas, Audrey Kennel, Florence Deauvieau, et al.
The American Journal of Tropical Medicine and Hygiene|January 27, 2007
Innate immune responses in human dendritic cells upon infection by chimeric yellow-fever dengue vaccine serotypes 1-4Florence Deauvieau, Violette Sanchez, Claire Balas, et al.
The American Journal of Tropical Medicine and Hygiene|July 14, 2006
Short report: immune response and occurrence of dengue infection in thai children three to eight years after vaccination with live attenuated tetravalent dengue vaccinePornthep Chanthavanich, Christine Luxemburger, Chukiat Sirivichayakul, et al.
Plos One|August 10, 2011
Stability of yellow fever virus under recombinatory pressure as compared with chikungunya virusCharles E McGee, Konstantin A Tsetsarkin, Bruno Guy, et al.
Vaccine|April 12, 2011
Live-attenuated, tetravalent dengue vaccine in children, adolescents and adults in a dengue endemic country: randomized controlled phase I trial in the PhilippinesRosario Z Capeding, Imelda A Luna, Emily Bomasang, et al.
Vaccine|August 19, 2004
Evaluation by flow cytometry of antibody-dependent enhancement (ADE) of dengue infection by sera from Thai children immunized with a live-attenuated tetravalent dengue vaccineBruno Guy, Pornthep Chanthavanich, Sophie Gimenez, et al.
Vector Borne and Zoonotic Diseases (Larchmont, N.Y.)|August 29, 2012
Evaluation of chimeric yellow fever 17D/dengue viral replication in ticksMária Kazimírová, Nathalie Mantel, Sandrine Raynaud, et al.
Human Vaccines & Immunotherapeutics|December 9, 2014
Assessment of bivalent and tetravalent dengue vaccine formulations in flavivirus-naïve adults in MexicoGustavo H Dayan, Juan-Francisco Galán-Herrera, Remi Forrat, et al.
Pageof 6

Showing results (21-30 of 53) with videos related to

Sort By:
Pageof 6
Vaccine|October 11, 2005
Immunogenicity and safety of two live-attenuated tetravalent dengue vaccine formulations in healthy Australian adultsScott Kitchener, Michael Nissen, Peter Nasveld, et al.
Journal of Virology|March 30, 2018
Improvement of the Dengue Virus (DENV) Nonhuman Primate Model via a Reverse Translational Approach Based on Dengue Vaccine Clinical Efficacy Data against DENV-2 and -4Veronique Barban, Nathalie Mantel, Aymeric De Montfort, et al.
The Journal of Infectious Diseases|December 15, 2010
Different innate signatures induced in human monocyte-derived dendritic cells by wild-type dengue 3 virus, attenuated but reactogenic dengue 3 vaccine virus, or attenuated nonreactogenic dengue 1-4 vaccine virus strainsClaire Balas, Audrey Kennel, Florence Deauvieau, et al.
The American Journal of Tropical Medicine and Hygiene|January 27, 2007
Innate immune responses in human dendritic cells upon infection by chimeric yellow-fever dengue vaccine serotypes 1-4Florence Deauvieau, Violette Sanchez, Claire Balas, et al.
The American Journal of Tropical Medicine and Hygiene|July 14, 2006
Short report: immune response and occurrence of dengue infection in thai children three to eight years after vaccination with live attenuated tetravalent dengue vaccinePornthep Chanthavanich, Christine Luxemburger, Chukiat Sirivichayakul, et al.
Plos One|August 10, 2011
Stability of yellow fever virus under recombinatory pressure as compared with chikungunya virusCharles E McGee, Konstantin A Tsetsarkin, Bruno Guy, et al.
Vaccine|April 12, 2011
Live-attenuated, tetravalent dengue vaccine in children, adolescents and adults in a dengue endemic country: randomized controlled phase I trial in the PhilippinesRosario Z Capeding, Imelda A Luna, Emily Bomasang, et al.
Vaccine|August 19, 2004
Evaluation by flow cytometry of antibody-dependent enhancement (ADE) of dengue infection by sera from Thai children immunized with a live-attenuated tetravalent dengue vaccineBruno Guy, Pornthep Chanthavanich, Sophie Gimenez, et al.
Vector Borne and Zoonotic Diseases (Larchmont, N.Y.)|August 29, 2012
Evaluation of chimeric yellow fever 17D/dengue viral replication in ticksMária Kazimírová, Nathalie Mantel, Sandrine Raynaud, et al.
Human Vaccines & Immunotherapeutics|December 9, 2014
Assessment of bivalent and tetravalent dengue vaccine formulations in flavivirus-naïve adults in MexicoGustavo H Dayan, Juan-Francisco Galán-Herrera, Remi Forrat, et al.
Pageof 6